Arrhythmia, Devices, Heart Failure
Read Time: 2 mins

The Subcutaneous Defibrillator – New Evidence and Developments

Copy Link
Published Online: May 17th 2016 European Journal of Arrhythmia & Electrophysiology, 2016;2(1):20–1 DOI:
Authors: Pier D Lambiase
Quick Links:
Article Information

The subcutaneous implantable cardioverter-defibrillator (S-ICD) is emerging as an important adjunct in the prevention of sudden cardiac death avoiding the long-term complications of transvenous leads. This editorial reviews that past year of developments, new clinical evidence and what the future challenges are in this field.


Subcutaneous implantable cardioverter-defibrillator (S-ICD), sudden cardiac death


The subcutaneous implantable cardioverter-defibrillator (S-ICD) is a disruptive technological change in our approach to ICD implantation avoiding the Achilles’ heel of the transvenous lead impantation in patients without pacing indications. The evidence base has been significantly expanded over the past 12 months with growing experience and longer-term follow-up.

In 2015, a pooled analysis of the two largest S-ICD series: the IDE Trial and EFFORTLESS Registry, evaluated the longer-term safety and efficacy of the S-ICD with 2 years’ follow-up.1–3By pooling these studies, the outcomes of 882 patients over 651±345 days (1,571.5 patient–years) give further support for the use of the S-ICD in appropriate patients.3 The success of shock therapy after up to five shocks for ventricular tachyarrhythmias was 98.2%, and the estimated 3-year inappropriate shock rate was 13.1%. The estimated all-cause mortality was 4.7% at 3 years with a total of 26 deaths, which was 2.9% of patients who underwent implantation, with only one known arrhythmic death (0.1%) due to Loeffler’s syndrome. Device-related complications occurred in 11.1% of patients at 3 years, but there was no S-ICD-related endocarditis, bacteraemia or lead failure. Indeed, data examining the learning curve of implantation demonstrates that the implant complications are improved with experience: the 6-month complication rate decreased by quartile of enrolment (Q1: 8.9%; Q4: 5.5%). The greater utilisation of dual-zone programming to minimise inappropriate shocks for supraventricular tachycardia (SVT) and T wave oversensing reduced inappropriate shocks by 35% in the pooled analysis from 6.9% in the first quartile of implanted patients to 4.5% in the final quartile. Furthermore, with an increased understanding of patient selection and the utilisation of post-implant exercise testing, to minimise T wave oversensing at increased heart rates in young active patients (± pre-implant exercise testing in rare disease cases e.g. hypertrophic cardiomyopathy), inappropriate shock rates can be further reduced. This is evident in the pooled analysis where once programming changes were made, inappropriate shocks rates declined to <2% per annum indicating patient screening and electrocardiogram (ECG) vector selection are critical in achieving optimal S-ICD device programming. Challenges remain to minimise the risk of T wave oversensing particularly in patients with complex congenital heart disease and cardiomyopathies and it may be necessary to consider alternative sensing electrode placement or integration of ECG sensing vectors to minimise this in certain cases.7

A question regarding the subsequent need for pacing in S-ICD recipients was answered in the pooled cohort with 3/882 requiring system replacement for right ventricular pacing or cardiac resynchronisation therapy (CRT) indications. The main determinants of pacing requirement are PR prolongation, New York Heart Association (NYHA) class and QRS width.4 The current selection of S-ICD patients indicates that conversion to a transvenous system is not a significant matter at this stage.

A further factor related to S-ICD has been the question of lack of anti-tachycardia pacing (ATP) to terminate (VT). Patients are excluded from S-ICD if they develop sustained monomorphic VT and in the pooled analysis 1.5% patients received more than one shock monomorphic VT. Applying the Painfree Rx II ATP efficacy to this group, this may have been reduced to 0.6% of the S-ICD population.5With the advent of Multicenter Automatic Defibrillator Implantation Trial – Reduce Inappropriate Therapy (MADIT-RIT), ICD programming is moving towards more prolonged detection times for VT and higher rate cut-offs as there is now evidence of a potential mortality benefit in avoiding shocks for VT.6Since the S-ICD is programmed at such higher rate cut-offs with a mean time to therapy of 15 seconds, there are some parallels with MADT-RIT programming. This controversial lack of antitachycardia pacing (ATP) in S-ICD has initiated two studies to address the question – A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy (PRAETORIAN), which is examining the outcomes of patients where there is equipoise between transvenous implantable (TV-ICD) versus S-ICD implantation utilising MADIT-RIT high rate and prolonged detection therapy criteria. The Untouched Registry is examining shock rates compared with the MADIT-RIT outcomes in primary prevention patients with ejection fraction <35%. These studies will provide important data on the exact role of ATP in these populations and whom to select for a device that can deliver ATP. Indeed, this subject is becoming an active field of research through the evolution of leadless pacing technologies, which are emerging this year.8,9Indeed, preliminary reports demonstrate that these systems could be integrated.10 It is highly likely that we will soon have the opportunity to deliver back-up bradycardia pacing and ATP in subgroups of S-ICD recipients. The on-going PRAETORIAN and Untouched studies will inform optimal patient selection.

At the time of writing we are seeing an exponential increase in S-ICD implantation in Europe and the US. It has been endorsed by the recent European Cardiac Society Guidelines on Ventricular Arrhythmias & Sudden Cardiac Death as a Class IIa indication for patients with an ICD indication without the need for pacing, CRT or ATP.11Indeed, the Class IIb indications say that “it may be considered as a useful alternative to the transvenous ICD system when venous access is difficult, after the removal of a transvenous ICD for infections or in young patients with a long-term need for ICD therapy”. The second-generation device has meant a 20% thinner generator, improved battery longevity and wireless remote monitoring making implantation and follow-up more straightforward. The next few years will inevitably see greater integration of leadless pacing and subcutaneous ICD systems. As nanotechnology and external power sources evolve, multi-chamber pacing using such leadless pacing ‘seeds’ may mean that transvenous devices will become obsolete as these implant and sensing technologies develop over the next century.12

Article Information:

Pier D Lambiase is supported by UCLH Biomedicine NIHR andreceives speaker/advisory fees and educational grants from Boston Scientific and Educational Grants from Medtronic. No funding was received for the publication of this article. This article is a short opinion piece and has not been submitted to external peer reviewers.
Published Online: 10 May 2016


Pier D Lambiase, Institute of Cardiovascular Science, University College London & Barts Heart Centre, West Smithfield, London EC1A 7BE. E:


This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.




1. Weiss R, Knight BP, Gold MR, et al., Safety and efficacy of a totally subcutaneous implantable cardioverter defibrillator, Circulation 2013;128:944–53.
2. Lambiase PD, Barr C, Theuns DA, et al., Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry, Eur Heart J, 2014;35:1657–653.
3. Burke MC, Gold MR, Knight BP, et al., Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry, J Am Coll Cardiol 2015;65:1605–15.
4. de Bie MK, Thijssen J, van Rees JB, et al., Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice, Heart 2013;99:1018–2.
5. Wathen MS, DeGroot PJ, Sweeney MO, et al.; PainFREE Rx II Investigators, Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results, Circulation 2004;110:2591–6.
6. Moss AJ, Schuger C, Beck CA, et al., Reduction in inappropriate therapy and mortality through ICD programming, N Engl J Med 2012;367:2275–83.
7. Maurizi N, Olivotto I, Olde Nordkamp LR, et al., Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy, Heart Rhythm 2016;13:457–63.
8. Reddy VY, Exner DV, Cantillon DJ, et al.; LEADLESS II Study Investigators, Percutaneous implantation of an entirely intracardiac leadless pacemaker, N Engl J Med 2015;373:1125–35.
9. Knops RE, Tjong FV, Neuzil P, et al., Chronic performance of a leadless cardiac pacemaker: 1-year follow-up of the LEADLESS trial, J Am Coll Cardiol 2015;65:1497–504.
10. Mondésert B, Dubuc M, Khairy P, et al., Combination of a leadless pacemaker and subcutaneous defibrillator: First in-human report, Heart Rhythm Case Reports, Vol. 1, Issue 6, p469–71.
11. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al., 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), Eur Heart J 2015;36:2793–867.
12. Auricchio A, Delnoy PP, Butter C, et al.; Collaborative Study Group. Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: results of the wireless stimulation endocardially for CRT (WiSE-CRT) study, Europace 2014;16:681–8.

Further Resources

Share this Article
Related Content In Heart Failure
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72